This inventor holds 1 USPTO granted patent. Top assignee: Innopharmax, Inc.. Active years: 2020.
Company Filing History:
Years Active: 2020
Title: Innovations in Cancer Therapy by Shu-Ping Hsueh
Introduction
Shu-Ping Hsueh is a notable inventor based in Taipei, Taiwan. He has made significant contributions to the field of cancer therapy through his innovative approaches and research. His work focuses on improving treatment methods for tumors, particularly through the use of gemcitabine.
Latest Patents
Shu-Ping Hsueh holds a patent for "Metronomic oral gemcitabine for cancer therapy." This patent describes compositions and methods for treating tumors in patients, including humans. The invention emphasizes the use of gemcitabine in self-emulsifying orally administered dosage forms. The method involves administering gemcitabine in a metronomic manner, which means delivering a therapeutic amount repeatedly over an extended period, preferably on a continuous schedule.
Career Highlights
Hsueh's career is marked by his dedication to advancing cancer treatment methodologies. His innovative patent reflects his commitment to improving patient outcomes through effective drug delivery systems. He works at Innopharmax, Inc., where he continues to develop and refine his ideas in the pharmaceutical field.
Collaborations
Shu-Ping Hsueh collaborates with esteemed colleagues such as Wei-Hua Hao and Chang-Shan Hsu. These partnerships enhance the research and development efforts at Innopharmax, Inc., contributing to the advancement of cancer therapies.
Conclusion
Shu-Ping Hsueh's work in cancer therapy exemplifies the impact of innovative thinking in medicine. His patent on metronomic oral gemcitabine represents a significant step forward in treating tumors effectively. Through his career and collaborations, Hsueh continues to contribute to the field of oncology, aiming to improve the lives of patients worldwide.